TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4 (TB4)
During the drug discovery process, preclinical/nonclinical toxicology studies are conducted to reveal a candidate molecules earliest potential toxic effects as it progresses from hit to lead and ultimately to a drug candidate, reducing the number of animals involved at later stages of drug discovery
Th17 cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases
Abbreviations HGF: hepatocyte growth factor ICIs: immune checkpoint inhibitors TME: tumor microenvironment EMT: epithelial-mesenchymal transition HNSCC: head and neck squamous cell carcinoma RTKs: receptor tyrosine kinases METex14: MET exon 14 skipping mutations NSCLC: non-small cell lung cancer CAFs: cancer-associated fibroblasts TAMs: tumor-associated macrophages MDSCs: myeloid-derived suppressor cells NK: natural killer DCs: dendritic cells ECM: extracellular matrix Chi3L1: chitinase-3-like-1 Treg: T regulatory CRC: colorectal cancer GC: gastric cancer IL-6R: interleukin-6 receptor MMPs: matrix metalloproteinases HIF1: hypoxia-inducible factor 1 IFN-: interferon-gamma HCC: hepatocellular carcinoma CTLs: cytotoxic T lymphocytes MSCs: Mesenchymal stromal cells CTLA-4: cytotoxic T-lymphocyte-associated protein 4 APCs: antigen-presenting cells ORR: objective response rate PFS: progression-free survival OS: overall survival GSK3: glycogen synthase kinase 3 References Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, et al
The primary differences are solubility and formulation compatibility
Retatrutide and cagrilintide are both investigational drugs not approved by the FDA
